References
- Catolona WJ, Richie JP, Scardino PT, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter trial of 6630 men. J Urol 1994; 151: 1283–90.
- Hodge KK, McNeal JE, Terris MK, et al. Random systemic versus directed ultrasound guided transrectal core biopsy of the prostate. J Urol 1989; 142: 71–5.
- Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993; 71: 2569–73.
- Huggins C, Hodges CV. Study on prostate cancer 1. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the
- Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49: 5–15.
- Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J
- Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993; 7: 17–24.
- Cervellino JC, Araujo CE, Pirisi C, Podskubka 0,
- Ferro MA, Gillatt D, Symes MO, Smith PJB. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Urology 1989; 34: 134–8.
- Droz JP, Smedt ED, Kattan J, Keuppens F, Khoury S, Mahler C, Denis L. Phase I trial of high-dose fosfestrol in
- Robertson CV, Robertson KM, Padilla GM, et al. Induction of apotosis by diethylstilbestrol in hormoneinsensitive prostate cancer cells. J Natl Cancer Inst 1996; 88: 908�17.
- Hartley-Asp B, Deinum J, Wallin M. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly. Mut Res 1985; 143: 231�5.
- Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76: 1428�34.
- Miller JI, Ahmann DR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostrate speci. c antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992; 147: 956�61.
- Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwart M, Fossa SD. Prostate-speci. c antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607�15.
- Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756�64.
- Smith DC, Redman BG, Flaherty LE, et al. A phase II trial if oral diethylstildiphosphate as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257�60.
- Kitahara S, Yoshida K, Ishizaki K, et al. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agents. Endocrine J 1997; 44: 527�32.
- Stege R, Erikson P, Carlstrom K. Orhidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids. Int J Andol 1987; 10: 581�7.
- Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J. B. Lippincott; 1985. 193�200.
- Labrie F. Intracrinology. Mol Cell Enocrinol 1991; 78: 113�18.
- Visacorpi T, Hytinen E, Koivisto P, et al. In vivo ampli. cation of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995; 9: 401�6.
- Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene ampli. cation: A possible mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314�19.
- Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. D5- Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci 1998; 95: 11083�8.